Carbon Dioxide Insufflation Colonoscopy in IBD Patients

Carbon Dioxide Insufflation Colonoscopy in Inflammatory Bowel Disease Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02563132

Enrollment

Registered

2015-09-29

Start date

2015-10-31

Completion date

2016-05-31

Last updated

2016-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonoscopy, Carbon Dioxide, Inflammatory Bowel Disease

Keywords

colonoscopy, carbon dioxide, inflammatory bowel disease

Brief summary

Carbon dioxide insufflation during colonoscopy significantly reduces discomfort (pain, bloating and flatulence) after the procedure. So far, it has not been studied in inflammatory bowel disease patients. The study was designed to evaluate discomfort after the carbon dioxide insufflation colonoscopy in comparison to standard air insufflation colonoscopy.

Detailed description

Carbon dioxide insufflation during colonoscopy significantly reduces discomfort (pain, bloating and flatulence) during up to 24 hours after the procedure. So far, it has not been studied in inflammatory bowel disease patients who represent specific patient population indicated for colonoscopy. They are characterized by younger age, structural changes of the colon including intestinal resections and need for repeated and frequently difficult procedures.The study was designed to evaluate discomfort during 24 hours after the carbon dioxide insufflation colonoscopy in comparison to standard air insufflation colonoscopy.

Interventions

PROCEDURECarbon dioxide insufflation

Carbon dioxide insufflation during diagnostic colonoscopy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* known diagnosis of Crohn´s disease and ulcerative colitis * indication for diagnostic colonoscopy * informed consent * unsedated or minimally sedated procedure (\< 3 mg of midazolam)

Exclusion criteria

* planned incomplete or therapeutic procedure * deep sedation or general anesthesia * intestinal resection longer than ileocecal resection * isolated gastroduodenal or jejunal location of Crohn´s disease (L4) * ulcerative proctitis (E1)

Design outcomes

Primary

Measure	Time frame	Description
Bloating score 1 hour after the colonoscopy	1 hour	Bloating severity on continuous scale 0-10 (0 = none, 10 = worst) 1 hour after colonoscopy

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026